These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 8847282

  • 1. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats.
    Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S.
    J Appl Physiol (1985); 1995 Dec; 79(6):2122-31. PubMed ID: 8847282
    [Abstract] [Full Text] [Related]

  • 2. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats.
    Chen SJ, Chen YF, Opgenorth TJ, Wessale JL, Meng QC, Durand J, DiCarlo VS, Oparil S.
    J Cardiovasc Pharmacol; 1997 Jun; 29(6):713-25. PubMed ID: 9234651
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. ZD1611, an orally active endothelin-A receptor antagonist, prevents chronic hypoxia-induced pulmonary hypertension in the rat.
    Bialecki RA, Fisher CS, Abbott BM, Barthlow HG, Caccese RG, Stow RB, Rumsey J, Rumsey W.
    Pulm Pharmacol Ther; 1999 Jun; 12(5):303-12. PubMed ID: 10545286
    [Abstract] [Full Text] [Related]

  • 6. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats.
    Hill NS, Warburton RR, Pietras L, Klinger JR.
    J Appl Physiol (1985); 1997 Oct; 83(4):1209-15. PubMed ID: 9338430
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.
    Yuyama H, Fujimori A, Sanagi M, Koakutsu A, Sudoh K, Sasamata M, Miyata K.
    Eur J Pharmacol; 2004 Aug 02; 496(1-3):129-39. PubMed ID: 15288584
    [Abstract] [Full Text] [Related]

  • 10. Endothelin receptors blockade blunts hypoxia-induced increase in PAP in humans.
    Pham I, Wuerzner G, Richalet JP, Peyrard S, Azizi M.
    Eur J Clin Invest; 2010 Mar 02; 40(3):195-202. PubMed ID: 20415698
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prevention and reversal of hypoxic pulmonary hypertension by calcium antagonists.
    Stanbrook HS, Morris KG, McMurtry IF.
    Am Rev Respir Dis; 1984 Jul 02; 130(1):81-5. PubMed ID: 6742615
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Endothelin blockade in angiotensin II hypertension: prevention and treatment studies in the rat.
    Ficai S, Herizi A, Mimran A, Jover B.
    Clin Exp Pharmacol Physiol; 2001 Dec 02; 28(12):1100-3. PubMed ID: 11903325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.